Recombinant murine leukemia virus (MuLV) p30 protein is a viral capsid protein derived from MuLV, a retrovirus commonly used in research as a model for studying viral replication, oncogenesis, and gene therapy. The p30 protein forms part of the viral core and is essential for virion assembly and infectivity. Recombinant versions of MuLV p30 are often produced in vitro for use as antigens in assays, allowing the detection of viral proteins, immune responses, or antiviral activity in experimental systems. As a biomarker, p30 reflects viral presence, replication, and immune recognition in murine models or in vitro studies.
In research, recombinant MuLV p30 protein is widely used in immunological and virological assays. It serves as a target antigen in enzyme-linked immunosorbent assays (ELISAs) or Western blots to quantify viral load, monitor infection progression, and evaluate host immune responses. Researchers also use p30 to study retroviral assembly, screen for antiviral compounds, or develop vaccines and neutralizing antibodies. Its recombinant form provides a standardized and safe tool for investigating viral biology without the risks associated with handling live virus.
Clinically, while MuLV itself is not a human pathogen, recombinant p30 serves as a model biomarker in translational research for retroviral infections and retrovirus-based gene therapies. It helps in evaluating the efficacy of antiviral strategies, immune responses to viral vectors, and safety of gene therapy approaches in preclinical models. Overall, recombinant MuLV p30 bridges basic virology and immunology research with applications in retroviral vector design and therapeutic development.
This product is manufactured in Estonia by Icosagen.
| Size | 10 µg |
| Source Species | Mouse |
| Expression System | E. coli |
| Storage | -80°C |
| Alternative Names | Core polyprotein, capsid protein p30, Friend isolate |
